menu
    • menu

    Company profile for Aim ImmunoTech

    NEW Drugs in Dev: 3
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Aim ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida and focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the h...
    Aim ImmunoTech Inc. is an immuno-pharma company headquartered in Ocala, Florida and focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Aim ImmunoTechUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2117 SW Highway 484 Ocala, FL 34473
    Telephone
    Telephone
    352-448-7797
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://aimimmuno.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/40900582/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/AIMImmuno

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    BPI Europe

    BPI Europe

    Not Confirmed

    envelop Contact Supplier

    BPI Europe

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    AIM Immunotech Provides Routine Update On Annual Filings
    AIM Immunotech Provides Routine Update On Annual Filings

    13 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/13/3272939/29489/en/AIM-ImmunoTech-Provides-Routine-Update-on-Annual-Filings.html

    GLOBENEWSWIRE
    13 Apr 2026
    Share Share
    AIM Immunotech Joins Virtual Investor Closing Bell Event
    AIM Immunotech Joins Virtual Investor Closing Bell Event

    09 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/09/3270853/29489/en/AIM-ImmunoTech-to-Participate-in-Live-Virtual-Investor-Closing-Bell-Event.html

    GLOBENEWSWIRE
    09 Apr 2026
    Share Share
    AIM ImmunoTech Wins Japan Patent For Ampligen Combo Therapy
    AIM ImmunoTech Wins Japan Patent For Ampligen Combo Therapy

    18 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/18/3258177/29489/en/AIM-ImmunoTech-Announces-Final-Approval-of-Novel-Cancer-Therapy-Patent-in-Japan-Combining-Ampligen-with-Checkpoint-Inhibitors.html

    GLOBENEWSWIRE
    18 Mar 2026
    Share Share
    AIM ImmunoTech Announces Closing of its Rights Offering
    AIM ImmunoTech Announces Closing of its Rights Offering

    06 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/07/3251368/29489/en/AIM-ImmunoTech-Announces-Closing-of-its-Rights-Offering.html

    GLOBENEWSWIRE
    06 Mar 2026
    Share Share
    AIM ImmunoTech Signs Ampligen Phase 3 Trial Deal
    AIM ImmunoTech Signs Ampligen Phase 3 Trial Deal

    02 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/02/3247438/29489/en/AIM-ImmunoTech-Signs-Agreement-for-Planning-of-a-Proposed-Phase-3-Clinical-Trial-of-Ampligen-in-the-Treatment-of-Late-Stage-Pancreatic-Cancer.html

    GLOBENEWSWIRE
    02 Mar 2026
    Share Share
    AIM ImmunoTech Reminds Stockholders of March 3, 2026
    AIM ImmunoTech Reminds Stockholders of March 3, 2026

    27 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/27/3246545/29489/en/AIM-ImmunoTech-Reminds-Stockholders-of-March-3-2026-Expiration-Date-and-Updates-Terms-of-Previously-Announced-Rights-Offering.html

    GLOBENEWSWIRE
    27 Feb 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search